Mr Ward is currently senior vice president and president of the cardiovascular sector at Medtronic. In this role, Mr Ward is responsible for all worldwide operations of the coronary, peripheral, endovascular, structural heart disease and revascularization and surgical therapies businesses.
Timothy Nelson, president and CEO of Map Pharmaceuticals, said: “The addition of Scott’s product development and commercialization experience to the board of directors will benefit Map Pharmaceuticals as we continue to advance our two lead drug candidates for pediatric asthma and acute migraine through Phase III clinical trials and potential commercialization.”